Live Biotherapeutics Market Report 2026

Live Biotherapeutics Market Overview

• Live Biotherapeutics market size has reached to $92.31 billion in 2025 • Expected to grow to $182.52 billion in 2030 at a compound annual growth rate (CAGR) of 14.7% • Growth Driver: Rising Prevalence Of Gastrointestinal Disorders And Inflammatory Bowel Diseases Supporting The Market Expansion Through Growing Demand For Microbiome-Based Therapies • Market Trend: Advanced Multi-Omics And Microbiome Science Platforms Accelerate Innovation In Live Biotherapeutics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Live Biotherapeutics Market?

Live biotherapeutics are biological medicinal products that contain live microorganisms, such as bacteria or yeasts, which are intended to prevent, treat, or manage diseases in humans. These products work by interacting with the body’s microbiota or physiological systems to produce a therapeutic effect and are developed under controlled pharmaceutical standards to ensure safety, quality, and efficacy. The main product types of live biotherapeutics include single strain live biotherapeutics, multi strain live biotherapeutics, genetically engineered live biotherapeutics, fecal microbiota based therapeutics, and bacterial consortia therapeutics. Single strain live biotherapeutics refer to therapeutic products containing a single live microorganism strain intended to prevent, manage, or treat specific diseases. These products are developed using microorganism types including bacteria based therapeutics, yeast based therapeutics, viral or bacteriophage based therapeutics, and mixed microbial therapeutics and are administered through oral, rectal, and other routes of administration. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and the key applications include gastrointestinal disorders, infectious diseases, oncology supportive care, metabolic disorders, autoimmune and inflammatory diseases, neurological disorders, dermatological conditions, and respiratory disorders.

What Is The Live Biotherapeutics Market Growth Forecast?

The live biotherapeutics market size is expected to see rapid growth in the next few years. It will grow to $182.52 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to advancements in precision microbiome engineering technologies, increasing regulatory approvals for live biotherapeutic products, rising investments in microbiome-based drug pipelines, expansion of personalized medicine approaches, growing demand for targeted non-antibiotic therapies. Major trends in the forecast period include rising integration of microbiome-based therapeutics in hospital clinical protocols, increasing adoption of personalized microbiome modulation therapies, growing standardization and regulatory harmonization of live biotherapeutic products, expanding clinical trials for next-generation engineered microbial therapies, increasing demand for non-antibiotic treatment alternatives in chronic disease management.

Global Live Biotherapeutics Market Segmentation

1) By Product Type: Single Strain Live Biotherapeutics, Multi Strain Live Biotherapeutics, Genetically Engineered Live Biotherapeutics, Fecal Microbiota Based Therapeutics, Bacterial Consortia Therapeutics 2) By Microorganism Type: Bacteria Based Therapeutics, Yeast Based Therapeutics, Viral Or Bacteriophage Based Therapeutics, Mixed Microbial Therapeutics 3) By Route Of Administration: Oral, Rectal, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By Application: Gastrointestinal Disorders, Infectious Diseases, Oncology Supportive Care, Metabolic Disorders, Autoimmune And Inflammatory Diseases, Neurological Disorders, Dermatological Conditions, Respiratory Disorders Subsegments: 1) By Single Strain Live Biotherapeutics: Lactobacillus Based Therapeutics, Bifidobacterium Based Therapeutics, Clostridium Based Therapeutics, Saccharomyces Based Therapeutics, Escherichia Coli Based Therapeutics, Bacillus Based Therapeutics 2) By Multi Strain Live Biotherapeutics: Lactobacillus And Bifidobacterium Combinations, Gut Microbiota Restoration Consortia, Anaerobic Bacterial Mixtures, Synbiotic Multi Strain Therapeutics, Immunomodulatory Microbial Combinations, Disease Specific Microbial Cocktails 3) By Genetically Engineered Live Biotherapeutics: Synthetic Biology Based Therapeutics, Clustered Regularly Interspaced Short Palindromic Repeats Engineered Microbial Therapeutics, Metabolite Producing Engineered Bacteria, Targeted Drug Delivery Microorganisms, Gene Editing Enabled Microbial Therapies, Recombinant Probiotic Therapeutics 4) By Fecal Microbiota Based Therapeutics: Fecal Microbiota Transplantation Products, Oral Fecal Microbiota Transplantation Capsules, Donor Derived Microbial Suspensions, Standardized Stool Derived Therapeutics, Rectal Microbiota Therapeutics, Lyophilized Fecal Microbiota Products 5) By Bacterial Consortia Therapeutics: Defined Bacterial Consortium Therapeutics, Rationally Designed Microbial Communities, Commensal Bacteria Therapeutics, Spore Forming Bacterial Consortia, Precision Microbiome Consortia, Next Generation Microbial Ecosystem Therapeutics

What Is The Driver Of The Live Biotherapeutics Market?

The rising prevalence of gastrointestinal disorders and inflammatory bowel diseases (IBD) is expected to propel the growth of the live biotherapeutics market going forward. Gastrointestinal disorders and inflammatory bowel diseases are chronic digestive system conditions that cause inflammation, immune dysfunction, abdominal pain, diarrhea, and damage to the gastrointestinal tract. The rising prevalence of gastrointestinal disorders and inflammatory bowel diseases is primarily driven by unhealthy dietary habits and increased processed food consumption, which disrupts gut microbiota and contributes to chronic intestinal inflammation. Live biotherapeutics help in gastrointestinal disease management by restoring microbial balance, improving gut health, reducing intestinal inflammation, and providing targeted microbiome-based therapeutic solutions for chronic digestive disorders. For instance, in February 2025, according to Crohn's & Colitis Australia, an Australia-based national organization, the projected prevalence of inflammatory bowel disease (IBD) in Australia is expected to increase from 20,511,881 cases in 2023 to 23,067,771 cases by 2030. Therefore, the rising prevalence of gastrointestinal disorders and inflammatory bowel diseases is driving the growth of the live biotherapeutics industry.

Key Players In The Global Live Biotherapeutics Market

Major companies operating in the live biotherapeutics market are Ferring Pharmaceuticals SA, Rebiotix Inc., Seres Therapeutics Inc., MaaT Pharma SA, Vedanta Biosciences Inc., Infant Bacterial Therapeutics AB, EnteroBiotix Limited, AOB Pharma Inc., BiomX Inc., Microbiotica Limited, Azitra Inc., MRM Health NV, BiomeBank Pty Ltd, Siolta Therapeutics Inc., Servatus Biopharmaceuticals Pty Ltd, Scioto Biosciences Inc.

Global Live Biotherapeutics Market Trends and Insights

Major companies operating in the live biotherapeutics market are focusing on developing advanced solutions, such as integrated multi-omics microbiome platforms, to enhance microbiome research, improve therapeutic discovery, and accelerate the development of next-generation live biotherapeutic products. Integrated multi-omics microbiome platforms refer to advanced scientific systems that combine microbiome, metabolomics, bioinformatics, and AI-driven analytics to generate comprehensive biological insights for therapeutic development. For instance, in November 2024, Cmbio, a Denmark-based microbiome and metabolomics science company, launched a unified global brand integrating Clinical Microbiomics, CosmosID, MS-Omics, DNASense, and Microba’s Research Services Unit under one platform. The new platform combines GxP-certified laboratory services, AI-powered bioinformatics, and scalable multi-omics technologies to support microbiome innovation across pharmaceutical, biotechnology, and healthcare sectors, enabling faster and more standardized microbiome-based therapeutic research and development.

What Are Latest Mergers And Acquisitions In The Live Biotherapeutics Market?

In October 2023, Kanvas Biosciences, a US-based microbiome therapeutics company, acquired key assets from Federation Bio for an undisclosed amount. This acquisition strengthens Kanvas Biosciences’ capabilities in the development and manufacturing of microbiome-based therapeutics and live biotherapeutic products by expanding its bioprocessing infrastructure and microbiome platform technologies. Federation Bio is a US-based company specializing in the development of microbiome therapeutics and live biotherapeutic products.

Regional Outlook

North America was the largest region in the live biotherapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Live Biotherapeutics Market?

The live biotherapeutics market consists of sales of spore-forming microbial therapeutics, yeast-derived live biotherapeutics, probiotic therapeutics, microbiome restoration therapies, and synthetic microbial therapeutics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Live Biotherapeutics Market Report 2026?

The live biotherapeutics market research report is one of a series of new reports from The Business Research Company that provides live biotherapeutics market statistics, including live biotherapeutics industry global market size, regional shares, competitors with a live biotherapeutics market share, detailed live biotherapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the live biotherapeutics industry. This live biotherapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.